Research Topics
Species | Christopher BenzSummaryAffiliation: Buck Institute for Age Research Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305Jason M Held
Buck Institute for Research on Aging, Novato, CA 94945, USA
Mol Cancer Res 10:1120-32. 2012....
Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsiesMichael D Mattie
UCSF Comprehensive Cancer Center, Department of Urology, San Francisco, California 94115, USA
Mol Cancer 5:24. 2006..Here we describe a novel combination of linear amplification and labeling of miRNA for highly sensitive expression microarray profiling requiring only picogram quantities of purified microRNA...- Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcomeVincent Vuaroqueaux
Stiftung Tumorbank Basel, Lörracherstrasse 50, 4125 Riehen, Switzerland
Breast Cancer Res 9:R33. 2007..We investigated whether mRNA levels of E2F1, a key transcription factor involved in proliferation, differentiation and apoptosis, could be used as a surrogate marker for the determination of breast cancer outcome... - Aging impacts transcriptomes but not genomes of hormone-dependent breast cancersChristina Yau
Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
Breast Cancer Res 9:R59. 2007..Except for inherited forms of breast cancer, however, there is little genetic or epigenetic understanding of the biological basis linking aging with sporadic breast cancer incidence and its clinical behavior... - Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancersChristina Yau
Buck Institute for Age Research, Redwood Boulevard, Novato, California 94945, USA
Breast Cancer Res 10:R61. 2008..Oxidative stress can modify estrogen receptor (ER) structure and function, including induction of progesterone receptor (PR), altering the biology and clinical behavior of endocrine responsive (ER-positive) breast cancer... - Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, CaliforniaRochelle R Ereman
County of Marin, Department of Health and Human Services, 20 North San Pedro Road, San Rafael, CA 94903, USA
BMC Public Health 10:228. 2010.... - Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancerYamei Zhou
Buck Institute for Age Research, Novato, CA 94945, USA
BMC Cancer 7:59. 2007..Signaling pathways that converge on two different transcription factor complexes, NFkappaB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen... 
Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancersChristopher C Benz
Buck Institute for Age Research, Novato, CA 94945, USA
Genes Chromosomes Cancer 45:983-94. 2006....- Geographic excess of estrogen receptor-positive breast cancerChristopher C Benz
Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, Novato, California 94945, USA
Cancer Epidemiol Biomarkers Prev 12:1523-7. 2003..The progressive increase in breast cancer incidence rates observed in Marin County over the past decade is occurring in women with high prevalence of risk factors predisposing toward excess development of ER+/PR+ breast cancer... - Impact of aging on the biology of breast cancerChristopher C Benz
Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
Crit Rev Oncol Hematol 66:65-74. 2008..g. estrogen receptor, ER) and growth factor receptor (e.g. HER2) expression, supporting the conclusion that the biology of breast cancer is age-dependent... - Novel pathways associated with quinone-induced stress in breast cancer cellsChristopher C Benz
Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, Novato, CA 94945, USA
Drug Metab Rev 38:601-13. 2006.... - Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screenGary K Scott
Program of Cancer and Development Therapeutics, Buck Institute for Age Research, Novato, California 94945, USA
Mol Cancer Ther 1:385-92. 2002..These findings suggest that further studies are warranted to determine whether ErbB2-positive human cancers represent unusually sensitive clinical targets for HDAC inhibitor therapy... - Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125bGary K Scott
Buck Institute for Age Research, Novato, California 94945, USA
J Biol Chem 282:1479-86. 2007..These results illustrate the feasibility of using miRNAs as a therapeutic strategy to suppress oncogene expression and function... - Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6Gary K Scott
Buck Institute for Age Research, Novato, CA 94945, USA
Mol Cancer Res 6:1250-8. 2008.... - Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomesDaryl C Drummond
Hermes Biosciences, Inc, South San Francisco, Buck Institute for Age Research, Novato, California 94945, USA
Clin Cancer Res 11:3392-401. 2005.... - Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancerCorina Marx
Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd, Novato, CA 94945, USA
Mol Pharmacol 71:1525-34. 2007.... - Rapid alteration of microRNA levels by histone deacetylase inhibitionGary K Scott
Program of Cancer and Developmental Therapeutics, Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
Cancer Res 66:1277-81. 2006..These findings emphasize the importance of post-transcriptional mRNA regulation by HDACi in addition to their established effects on promoter-driven gene expression... - Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcriptionCorina Marx
Program of Cancer and Development Therapeutics, Buck Institute for Age Research, Novato, CA 94945, USA
Assay Drug Dev Technol 4:273-84. 2006.... - ErbB2 activation of ESX gene expressionRichard M Neve
Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
Oncogene 21:3934-8. 2002..These results indicate that the ESX promoter represents a transcriptional target of ErbB2, and ESX expression may represent a downstream mediator of ErbB2 signaling and ErbB2-induced gene expression... - Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancersYamei Zhou
Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd, Novato, CA 94945, USA
Int J Biochem Cell Biol 37:1130-44. 2005.... - Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002Christopher Benz
Buck Institute, Novato, CA, USA
Breast Cancer Res Treat 78:127-31. 2003 - Vitamin K3 (menadione)-induced oncosis associated with keratin 8 phosphorylation and histone H3 arylationGary K Scott
Program of Cancer and Developmental Therapeutics, Buck Institute for Age Research, 8001 Red-wood Blvd, Novato, CA 94945, USA
Mol Pharmacol 68:606-15. 2005..These findings delineate new pathways associated with K3-induced stress and suggest a potentially novel role for H3 Cys110 as a nuclear stress sensor... - Essential cysteine-alkylation strategies to monitor structurally altered estrogen receptor as found in oxidant-stressed breast cancersJose E Meza
Buck Institute for Age Research (Program of Cancer and Developmental Therapeutics, Novato, CA 94945, USA
Anal Biochem 320:21-31. 2003..These improved analytical strategies should facilitate the monitoring of structurally altered endogenous ER produced within oxidant-stressed human breast cancer cells... - ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitinationCorina Marx
Buck Institute for Age Research, Novato, California 94945, USA
Cancer Res 70:3709-17. 2010.... - Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sitesChristian Atsriku
Buck Institute for Age Research, Novato, California 94945, USA
Mol Cell Proteomics 8:467-80. 2009.... - Ageing, oxidative stress and cancer: paradigms in parallaxChristopher C Benz
Christopher C Benz and Christina Yau are at the Buck Institute for Age Research, Novato, California 94945, USA
Nat Rev Cancer 8:875-9. 2008..of gene expression in age-controlled breast cancer cases indicate that this deduction is false, posing parallax views of these two paradigms, and highlighting the unanswered question: does ageing cause or simply permit cancer development?.. - A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cellsDavid J Britton
Buck Institute for Age Research, Novato, California 94945, USA
J Am Soc Mass Spectrom 19:729-40. 2008.... - Meeting report: Translational Research at the Aging and Cancer InterfaceChristopher C Benz
Buck Institute for Age Research, Novato, California, USA
Cancer Res 67:4560-3. 2007 - Risk factors for estrogen receptor-positive breast cancerE Shelley Hwang
Department of Surgery, University of California, San Francisco, Cancer Center, 94115, USA
Arch Surg 140:58-62. 2005..Some risk factors associated with breast cancer may be more predictive of estrogen receptor (ER)- positive than ER-negative tumors... - Age-associated biomarker profiles of human breast cancerSerenella Eppenberger-Castori
Stiftung Tumorbank Basel and Department of Research, University Clinics, Basel, Switzerland
Int J Biochem Cell Biol 34:1318-30. 2002..In particular, breast tumors arising in older patients have slower growth rates, are more likely to be ER-positive, and are less likely to be p53-positive, EGFR-positive or ErbB2-positive... - Age-dependent changes in breast cancer hormone receptors and oxidant stress markersJudy Quong
Comprehensive Cancer Center, University of California, San Francisco, CA, USA
Breast Cancer Res Treat 76:221-36. 2002.... - Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin usersAnjali S Kumar
Department of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, California, USA
Cancer Epidemiol Biomarkers Prev 17:1028-33. 2008.... - Identification of an epithelial-specific enhancer regulating ESX expressionRichard M Neve
Cancer Research Institute, University of California San Francisco, Box 0808, San Francisco, CA 94143 0808, USA
Gene 367:118-25. 2006..Understanding the regulation of this element will lend insight into mechanisms of epithelial differentiation and the etiology of breast cancer and may provide novel targets for cancer therapeutic intervention... - 655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterationsStefania Tommasi
National Cancer Institute Bari, Italy
Cell Oncol 29:241-8. 2007..In conclusion, these findings point to the existence of an association of ERBB2 allelic variants at both loci with specific breast tumor phenotypes and to the need of deeply investigate different gene SNPs association for risk defining... - Breast cancer growth prevention by statinsMichael J Campbell
Department of Surgery, University of California San Francisco Mt Zion Medical Center, Room C342, 1600 Divisadero, San Francisco, CA 94115, USA
Cancer Res 66:8707-14. 2006..These findings provide supporting rationale for future statin trials in breast cancer patients... - Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosisUlrik B Nielsen
Department of Anesthesia and Pharmaceutical Chemistry, University of California-San Francisco, SF General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110, USA
Biochim Biophys Acta 1591:109-118. 2002..This strategy should be applicable to generate immunotherapeutics for other malignancies by selecting phage antibodies for internalization into other tumor types and using the scFv to target liposomes or other nanoparticles... - A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypesAnjali S Kumar
J Clin Oncol 24:2127; author reply 2127-8. 2006 - Clinical trials are required to prove the chemopreventive worth of statinsAnjali S Kumar
Arch Intern Med 166:1143; author reply 1144. 2006 - Hyperplasia, reduced E-cadherin expression, and developmental arrest in mammary glands oxidatively stressed by loss of mitochondrial superoxide dismutaseHema Parmar
Department of Anatomy, University of California, San Francisco, CA 94143, USA
Breast 14:256-63. 2005..These findings suggest that excess oxidative stress from loss of SOD2 function can arrest mammary gland maturation and induce hyperplastic epithelium with early premalignant features... - Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal modelsDmitri B Kirpotin
Hermes Biosciences Inc, South San Francisco, CA, USA
Cancer Res 66:6732-40. 2006..Immunoliposomes capable of selective internalization in cancer cells in vivo may provide new opportunities for drug delivery... - Clinical development of histone deacetylase inhibitors as anticancer agentsDaryl C Drummond
Hermes Biosciences, Inc, South San Francisco, California 94080, USA
Annu Rev Pharmacol Toxicol 45:495-528. 2005.... - Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted deliveryJohn W Park
Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
Clin Cancer Res 8:1172-81. 2002..We previously showed that anti-HER2 immunoliposomes bind efficiently to and internalize in HER2-overexpressing cells in vitro, resulting in intracellular drug delivery... - Type and duration of exogenous hormone use affects breast cancer histologyAnjali S Kumar
Department of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, California, 94602, USA
Ann Surg Oncol 14:695-703. 2007..We conducted this investigation to assess whether the type of hormone used (none, estrogen, progesterone, or combined) and duration of use influences subsequent breast cancer histology... - Future directions of liposome- and immunoliposome-based cancer therapeuticsJohn W Park
UCSF Comprehensive Cancer Center, San Francisco, CA 94115-1710, USA
Semin Oncol 31:196-205. 2004.... - Redox control of zinc finger proteinsMichael A Baldwin
Mass Spectrometry Facility, Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, USA
Methods Enzymol 353:54-69. 2002 - Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cellsAudrey Roth
Department of Anesthesia, University of California at San Francisco, Room 3C38, 1001 Potrero Avenue, San Francisco, CA 94110, USA
Mol Cancer Ther 6:2737-46. 2007..Further studies on intracellular tracking of endocytosed liposomal drugs will help identify and overcome the barriers limiting the potency of liposomal drugs...
Research Grants
- THERAPEUTIC MODULATION OF BREAST CANCER ONCOGENESChristopher Benz; Fiscal Year: 2006..abstract_text> ..
- THERAPEUTIC MODULATION OF BREAST CANCER ONCOGENESChristopher Benz; Fiscal Year: 2007..tumor-targeted uptake of selected candidates by encapsulation into anti-ErbB2 immunoliposomes (ILs), and these ErbB2 receptor- and promoter-targeted ILs agents will be evaluated in vivo for further clinical development ..
- DEFECTIVE ESTROGEN RECEPTORS IN BREAST TUMORSChristopher Benz; Fiscal Year: 2007..Together, these aims will relate oxidant stress responses with specific oxER-associated mechanistic pathways, and validate the clinical significance of measuring oxER-associated parameters in human breast tumors. ..
- Biology of Breast Cancers Arising in Older WomenChristopher Benz; Fiscal Year: 2007..abstract_text> ..
- THERAPEUTIC MODULATION OF BREAST CANCER ONCOGENESChristopher Benz; Fiscal Year: 2002....
- THERAPEUTIC MODULATION OF BREAST CANCER ONCOGENESChristopher Benz; Fiscal Year: 2003..abstract_text> ..
- Mass spectrometry to decode PTM patterns and enhance the Biomarker utility of ERChristopher Benz; Fiscal Year: 2010....